Oncolytics Biotech (TSE:ONC) Insider Buys C$34,220.00 in Stock

Oncolytics Biotech Inc. (TSE:ONC) insider Jared Ryan Kelly acquired 29,500 shares of the business’s stock in a transaction on Thursday, February 12th. The shares were bought at an average cost of C$1.16 per share, with a total value of C$34,220.00. Following the completion of the acquisition, the insider owned 109,000 shares of the company’s stock, valued at approximately C$126,440. This trade represents a 37.11% increase in their position.

Jared Ryan Kelly also recently made the following trade(s):

• On Wednesday, February 11th, Jared Ryan Kelly bought 5,600 shares of Oncolytics Biotech stock. The stock was purchased at an average cost of C$1.15 per share, for a total transaction of C$6,440.00.

Oncolytics Biotech Trading Down 1.3%

Shares of Oncolytics Biotech stock opened at C$14.90 on Monday. Oncolytics Biotech Inc. has a 12-month low of C$0.44 and a 12-month high of C$2.08. The stock has a market capitalization of C$1.50 billion, a P/E ratio of -40.27 and a beta of 0.80. The company has a 50-day simple moving average of C$14.90 and a 200 day simple moving average of C$13.19. The company has a quick ratio of 8.86, a current ratio of 2.99 and a debt-to-equity ratio of 11.75.

Oncolytics Biotech (TSE:ONC) last issued its quarterly earnings data on Wednesday, November 12th. The company reported C($0.14) earnings per share for the quarter. Research analysts expect that Oncolytics Biotech Inc. will post -0.41 earnings per share for the current fiscal year.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.